NIH researchers report that in severe influenza, survival improves at late stages only when antivirals are combined with therapies that repair lung damage or limit harmful T-cell responses, explaining why anti-inflammatory treatments alone are often ineffective.

Evaxion A/S is advancing its cytomegalovirus (CMV) vaccine program, EVX-V1, with new data demonstrating protective effects of lead antigens in the program. EVX-V1 is a next-generation, multicomponent vaccine program combining novel AI-discovered antigens with AI-optimized versions of established CMV vaccine antigens.

Mabloc LLC has established a strategic partnership with Instituto Butantan to co-develop and manufacture MBL-YFV-01, a monoclonal antibody therapy for yellow fever virus (YFV) infection, including emergency post-exposure use.

South Korean researchers led by Lee In-suk of Yonsei University have reported the most complete oral microbiome catalog to date, with more than 72,000 genomes. Detailed in Cell Host & Microbe on Nov. 12, 2025, the database is expected to serve as a universal platform for academia and enable “precision microbiome medicine” for the industry, Lee told BioWorld.

Scynexis Inc. has announced that a novel series of antifungal compounds utilizing its proprietary triterpenoid antifungal platform are among five projects funded by a federal grant awarded to the new accelerator consortium led by researchers from Hackensack Meridian Center for Discovery and Innovation (CDI) and the Johns Hopkins Bloomberg School of Public Health.

GSK plc and the Fleming Initiative have announced six major new research programs to find new ways to slow the progress of antimicrobial resistance (AMR). The Fleming Initiative is a collaboration established by Imperial College London and Imperial College Healthcare NHS Trust to help tackle AMR. Each of the new programs will begin by early next year and are fully funded for 3 years.